This is a Phase 1 study during which patients with low or intermediate-1 risk
myelodysplastic syndromes (MDS) will receive investigational study drug ARRY-614.
This study has 2 parts. In the first part, patients will receive increasing doses of study
drug in order to achieve the highest dose of the study drug possible that will not cause
unacceptable side effects. Approximately 50 patients from the US will be enrolled in Part 1
(Active, not recruiting).
In the second part of the study, patients will receive the best dose of study drug
determined from the first part of the study and will be followed to see what side effects
and effectiveness the study drug has, if any, in treating the cancer. Approximately 30
patients from the US will be enrolled in Part 2 (Active, not recruiting).
Study Status: Active, not recruiting
Drug: ARRY-614, p38/Tie2 inhibitor; oral
Information provided by:
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland, Ohio 44195